Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Caitlan Clancy

Podiatrist Atlantis, FL Doctor of Podiatric Medicine

NPI 1013405935 CMS profile 7226309

180 Jfk Dr Ste 100, Atlantis, FL 33462

Open in the dashboard

General payments

$9,999

119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Caitlan Clancy of Atlantis, FL is reported in the CMS Open Payments database as having received $9,999 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,160 14
2024 General $1,360 17
2023 General $2,398 30
2022 General $3,196 29
2021 General $1,645 24
2020 General $168 3
2019 General $73 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Caitlan Clancy
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Caitlan Clancy were reported at $1,160. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Caitlan Clancy Podiatrist median Middle half National median
2019 $73 $196 $72–$601 $163
2020 $168 $118 $38–$335 $114
2021 $1,645 $169 $57–$573 $132
2022 $3,196 $220 $74–$782 $149
2023 $2,398 $208 $71–$635 $160
2024 $1,360 $237 $87–$681 $164
2025 $1,160 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $3,598 46 payments
  2. Arthrex, Inc. $2,335 17 payments
  3. Treace Medical Concepts, Inc. $757 11 payments
  4. Integra LifeSciences Corporation $410 7 payments
  5. Flower Orthopedics Coporation $386 10 payments
  6. Biocomposites Inc $334 3 payments
  7. DePuy Synthes Sales Inc. $305 3 payments
  8. Linvatec Corporation $266 2 payments
  9. Smith+Nephew, Inc. $263 3 payments
  10. Acera Surgical, Inc. $247 2 payments
  11. Other $1,097 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,299 108 payments
  2. Education $1,356 2 payments
  3. Travel and Lodging $1,344 9 payments
Products named General payments · program years 2019–2025
  1. VARIAX $935 12 payments
  2. ORTHOLOC 3DI $904 11 payments
  3. LAPIPLASTY SYSTEM $708 9 payments
  4. PROSTEP $511 5 payments
  5. PRIMATRIX $410 7 payments
  6. INTEGRA DERMAL REGENERATION TEMPLATE $410 7 payments
  7. Integra Recon-Skin And Wound $292 4 payments
  8. Integra Recon-Skin And Wound $292 4 payments
  9. Integra Recon-Skin And Wound $292 4 payments
  10. VITOSS $279 4 payments
  11. Other $5,060 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

186

Median for Podiatry: 160

Drug cost

$1,369

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Generic 19 $433
Gabapentin Generic 51 $211
Cephalexin Generic 18 $210
Ketoconazole Generic 12 $183
Meloxicam Generic 58 $128
Methylprednisolone Generic 16 $120
Terbinafine Hcl Generic 12 $83

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$68,403

Of which drugs: $12,312

Medicare patients

203

Average age 75

Services billed

945

130 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Ischemic heart disease 37%
Diabetes 29%
Osteoporosis 29%
Chronic kidney disease 27%
Depression 27%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 41 53 $38

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record